AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37331522 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 172
Study 37331522 — intervention group
Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 172
Study 33657912 — intervention group
Group type: EXPERIMENTAL
Intervention: Information Prescription (IP) prescribed by the physician plus routine oral information
Number of subjects: 120
Study 33657912 — intervention group
Group type: COMPARATOR
Intervention: Routine oral information by nurse or physician (control group)
Number of subjects: 120
Study 32351061 — intervention group
Group type: EXPERIMENTAL
Intervention: Phlogenzym (systemic enzyme therapy)
Number of subjects: 60
Study 32351061 — intervention group
Group type: COMPARATOR
Intervention: Standard antibiotic therapy
Number of subjects: 60
Study 33783102 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative-pressure wound therapy with instillation (NPWTi)
Number of subjects: 20
Study 33646807 — intervention group
Group type: EXPERIMENTAL
Intervention: UP + SSRI (n = 18)
Number of subjects: 39
Study 33646807 — intervention group
Group type: COMPARATOR
Intervention: continued SSRI‐only (n = 21)
Number of subjects: 39
Study 33751054 — intervention group
Group type: EXPERIMENTAL
Intervention: QT3 (2.13% CT)
Number of subjects: 20
Study 33751054 — intervention group
Group type: COMPARATOR
Intervention: QT (0%, 1%, 2%, 3% CT)
Number of subjects: 20
Study 32593287 — intervention group
Group type: EXPERIMENTAL
Intervention: HFNC with oxygen flow rate at 40 L/min
Number of subjects: 65
Study 32593287 — intervention group
Group type: EXPERIMENTAL
Intervention: HFNC with oxygen flow rate at 60 L/min
Number of subjects: 65
Study 32593287 — intervention group
Group type: EXPERIMENTAL
Intervention: HFNC with oxygen flow rate at 40 L/min or 60 L/min
Number of subjects: 65
Study 32593287 — intervention group
Group type: COMPARATOR
Intervention: NPA
Number of subjects: 65
Study 33556170 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed tomography staging
Number of subjects: 149
Study 33556170 — intervention group
Group type: COMPARATOR
Intervention: Institutional computed tomography staging
Number of subjects: 149
Study 32132317 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX)
Number of subjects: 196
Study 32132317 — intervention group
Group type: COMPARATOR
Intervention: Propofol (PROP)
Number of subjects: 196
Study 35896153 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief psychotherapy
Number of subjects: 177
Study 35896153 — intervention group
Group type: EXPERIMENTAL
Intervention: Immature defenses assessment at baseline
Number of subjects: 177
Study 34110393 — intervention group
Group type: EXPERIMENTAL
Intervention: Child protection system notification(s) only
Number of subjects: 1635
Study 34110393 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigation(s) (not substantiated)
Number of subjects: 1635
Study 34110393 — intervention group
Group type: EXPERIMENTAL
Intervention: Substantiated maltreatment
Number of subjects: 1635
Study 34110393 — intervention group
Group type: EXPERIMENTAL
Intervention: Ever placed in out‐of‐home care
Number of subjects: 1635
Study 34110393 — intervention group
Group type: COMPARATOR
Intervention: No child protection system contact (Control)
Number of subjects: 1635
Study 33189606 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum leucine levels
Number of subjects: 0
Study 33189606 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum isoleucine levels
Number of subjects: 0
Study 35227402 — intervention group
Group type: EXPERIMENTAL
Intervention: Written Exposure Therapy (WET)
Number of subjects: 126
Study 35227402 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 126
Study 35982520 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatial training (reaching toward sound sources)
Number of subjects: 20
Study 35982520 — intervention group
Group type: COMPARATOR
Intervention: Nonspatial control training (identifying sound amplitude modulations)
Number of subjects: 20
Study 34303267 — intervention group
Group type: COMPARATOR
Intervention: mFOLFOX (control arm)
Number of subjects: 120
Study 34303267 — intervention group
Group type: EXPERIMENTAL
Intervention: mFOLFIRI (experimental arm)
Number of subjects: 120
Study 34348343 — intervention group
Group type: EXPERIMENTAL
Intervention: Chitosan nanoparticle and gum (CN-G) applied twice daily for 4 weeks
Number of subjects: 24
Study 34348343 — intervention group
Group type: COMPARATOR
Intervention: Placebo (gum alone) applied twice daily for 4 weeks
Number of subjects: 24
Study 33099083 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased sense of witnessing agency (Self)
Number of subjects: 0
Study 33099083 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased sense of witnessing agency (Self)
Number of subjects: 0
Study 33099083 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased sense of body representational-emotional agency (Me)
Number of subjects: 0
Study 33099083 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased sense of body representational-emotional agency (Me)
Number of subjects: 0
Study 33099083 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased sense of reflective/narrative agency (I)
Number of subjects: 0
Study 33099083 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased sense of reflective/narrative agency (I)
Number of subjects: 0
Study 35583555 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax (800 mg orally daily) plus Fulvestrant (500 mg intramuscular; cycle 1: days 1 and 15; subsequent 28-day cycles: day 1)
Number of subjects: 103
Study 35583555 — intervention group
Group type: COMPARATOR
Intervention: Fulvestrant alone
Number of subjects: 103
Study 33682320 — intervention group
Group type: EXPERIMENTAL
Intervention: 177 Lu-PSMA-617 followed by docetaxel
Number of subjects: 140
Study 33682320 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 140
Study 32168393 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education interventions targeting healthcare providers or individuals, or both.
Number of subjects: 0
Study 32168393 — intervention group
Group type: COMPARATOR
Intervention: Health education interventions
Number of subjects: 0
Study 35869437 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotics (Lactobacillus acidophilus and Bifidobacterium longum 5x10^9 CFU)
Number of subjects: 60
Study 35869437 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 34499396 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid comprehensive telerehabilitation (HCTR)
Number of subjects: 386
Study 33051226 — intervention group
Group type: EXPERIMENTAL
Intervention: Small fenestration with clipping (eight metal clips around the peritoneal window)
Number of subjects: 0
Study 33051226 — intervention group
Group type: COMPARATOR
Intervention: Small fenestration alone (control arm)
Number of subjects: 0
Study 33051226 — intervention group
Group type: EXPERIMENTAL
Intervention: Small fenestration with clipping
Number of subjects: 0
Study 34937507 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D deficiency (25(OH)D < 10 ng/ml)
Number of subjects: 88
Study 32964526 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding interventions
Number of subjects: 0
Study 36007881 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine Monohydrate (5 g/day)
Number of subjects: 29
Study 36007881 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatyl-L-Leucine (5 g/day)
Number of subjects: 29
Study 36007881 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 34182952 — intervention group
Group type: EXPERIMENTAL
Intervention: Brigatinib
Number of subjects: 0
Study 34182952 — intervention group
Group type: COMPARATOR
Intervention: Other approved second-generation ALK TKI
Number of subjects: 0
Study 35636733 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 min of aerobic exercise only
Number of subjects: 280
Study 35636733 — intervention group
Group type: EXPERIMENTAL
Intervention: progressive resistance training only
Number of subjects: 280
Study 35636733 — intervention group
Group type: EXPERIMENTAL
Intervention: combined aerobic and progressive resistance training
Number of subjects: 280
Study 35636733 — intervention group
Group type: COMPARATOR
Intervention: flexibility/toning-control
Number of subjects: 280
Study 32458647 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy (N=150)
Number of subjects: 286
Study 32458647 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal Ablation (TA) (N=136)
Number of subjects: 286
Study 35895568 — intervention group
Group type: EXPERIMENTAL
Intervention: Sporting males (sm)
Number of subjects: 200
Study 35895568 — intervention group
Group type: EXPERIMENTAL
Intervention: Sporting females (sf)
Number of subjects: 200
Study 35895568 — intervention group
Group type: COMPARATOR
Intervention: Non-sporting males (nsm)
Number of subjects: 200
Study 35895568 — intervention group
Group type: COMPARATOR
Intervention: Non-sporting females (nsf)
Number of subjects: 200
Study 35793342 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise (morning jogging)
Number of subjects: 0
Study 35793342 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin supplement
Number of subjects: 0
Study 35793342 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of physical exercise and melatonin supplement
Number of subjects: 0
Study 35793342 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 33773532 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise rehabilitation program (two-week duration)
Number of subjects: 79
Study 33773532 — intervention group
Group type: COMPARATOR
Intervention: Routine chemotherapy care (control group)
Number of subjects: 79
Study 32015007 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month ART dispensing
Number of subjects: 79
Study 32015007 — intervention group
Group type: COMPARATOR
Intervention: 3-month ART dispensing
Number of subjects: 79
Study 35565901 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal undernutrition
Number of subjects: 1431
Study 35565901 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal higher education
Number of subjects: 1431
Study 34473402 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily PrEP regimen (TDF/FTC 300 mg/200 mg)
Number of subjects: 119
Study 34473402 — intervention group
Group type: COMPARATOR
Intervention: On-demand PrEP regimen (TDF/FTC 300 mg/200 mg)
Number of subjects: 119
Study 34269239 — intervention group
Group type: EXPERIMENTAL
Intervention: In situ hardening biphasic calcium phosphate (BCP)
Number of subjects: 42
Study 34269239 — intervention group
Group type: COMPARATOR
Intervention: Xenograft particles
Number of subjects: 42
Study 34269239 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups (BCP and xenograft)
Number of subjects: 42
Study 33091461 — intervention group
Group type: EXPERIMENTAL
Intervention: Tisseel®
Number of subjects: 147
Study 33091461 — intervention group
Group type: COMPARATOR
Intervention: Hemopatch®
Number of subjects: 147
Study 35249977 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position (group 1)
Number of subjects: 40
Study 35249977 — intervention group
Group type: COMPARATOR
Intervention: Seated position (group 2)
Number of subjects: 40
Study 33357325 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention including inpatient pharmacist‐led medication reconciliation, coordination of care, postdischarge phone calls, and postdischarge primary care visit.
Number of subjects: 1679
Study 33357325 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 1679
Study 33357325 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention.
Number of subjects: 1679
Study 35381390 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine (LT4) therapy
Number of subjects: 98
Study 35381390 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 32918266 — intervention group
Group type: EXPERIMENTAL
Intervention: Permethrin 1%
Number of subjects: 444
Study 32918266 — intervention group
Group type: EXPERIMENTAL
Intervention: Lindane 1%
Number of subjects: 444
Study 32918266 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimeticone 4%
Number of subjects: 444
Study 32918266 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 444
Study 32511749 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenecteplase 0.4 mg/kg (maximum 40 mg)
Number of subjects: 40
Study 32511749 — intervention group
Group type: COMPARATOR
Intervention: Alteplase 0.9 mg/kg (maximum 90 mg)
Number of subjects: 40
Study 35213344 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioception training
Number of subjects: 45
Study 35213344 — intervention group
Group type: COMPARATOR
Intervention: Control group (common rehabilitation training)
Number of subjects: 45
Study 32739102 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin (BT) intraanal sphincteric injection
Number of subjects: 40
Study 32739102 — intervention group
Group type: COMPARATOR
Intervention: Bowel management program (BMP) and senna based laxatives (SBL)
Number of subjects: 40
Study 35278093 — intervention group
Group type: EXPERIMENTAL
Intervention: Tät II treatment focused on pelvic floor muscle training (PFMT) and bladder training (BT)
Number of subjects: 122
Study 35278093 — intervention group
Group type: COMPARATOR
Intervention: Information app (control group)
Number of subjects: 122
Study 32408933 — intervention group
Group type: EXPERIMENTAL
Intervention: Experienced hoist operators
Number of subjects: 16
Study 32408933 — intervention group
Group type: COMPARATOR
Intervention: Novice hoist operators
Number of subjects: 16
Study 32408933 — intervention group
Group type: EXPERIMENTAL
Intervention: Experienced hoist operators (in wind)
Number of subjects: 16
Study 32408933 — intervention group
Group type: COMPARATOR
Intervention: Novice hoist operators (in wind)
Number of subjects: 16
Study 32460583 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth communication skills training
Number of subjects: 36
Study 32460583 — intervention group
Group type: COMPARATOR
Intervention: In-person communication skills training
Number of subjects: 36
Study 33926904 — intervention group
Group type: EXPERIMENTAL
Intervention: CONSORT extension for randomised controlled trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE)
Number of subjects: 0
Study 33926904 — intervention group
Group type: COMPARATOR
Intervention: CONSORT 2010 statement
Number of subjects: 0
Study 33926904 — intervention group
Group type: COMPARATOR
Intervention: Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement
Number of subjects: 0
Study 33926904 — intervention group
Group type: COMPARATOR
Intervention: REporting of studies Conducted using Observational Routinely collected Data (RECORD) statement
Number of subjects: 0
Study 33926904 — intervention group
Group type: EXPERIMENTAL
Intervention: Eight items modified from the CONSORT 2010 statement and five new items
Number of subjects: 0
Study 34281641 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA
Number of subjects: 14
Study 34281641 — intervention group
Group type: EXPERIMENTAL
Intervention: PLIAGLIS
Number of subjects: 14
Study 34281641 — intervention group
Group type: COMPARATOR
Intervention: Control sites
Number of subjects: 14
Study 34281641 — intervention group
Group type: COMPARATOR
Intervention: Distal limb (treated and control limbs)
Number of subjects: 14
Study 32186050 — intervention group
Group type: EXPERIMENTAL
Intervention: De Qi group (deep needling with thick needles and manipulation, n = 17)
Number of subjects: 68
Study 32186050 — intervention group
Group type: COMPARATOR
Intervention: Non-De Qi group (shallow needling with thin needles and no manipulation, n = 51)
Number of subjects: 68
Study 32186050 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (De Qi and non-De Qi)
Number of subjects: 68
Study 32186050 — intervention group
Group type: EXPERIMENTAL
Intervention: De Qi occurrence time
Number of subjects: 68
Study 32186050 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of De Qi
Number of subjects: 68
Study 33470755 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 17-beta estradiol (TE) 100 mcg/d
Number of subjects: 66
Study 33470755 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral raloxifene 60 mg/d
Number of subjects: 66
Study 33470755 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprietary phytoestrogen compound, Rimostil 1000 mg twice/d
Number of subjects: 66
Study 33470755 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 32416181 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated baseline serum uric acid (sUA) levels (>6 mg/dL)
Number of subjects: 212
Study 32416181 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline serum uric acid levels
Number of subjects: 212
Study 35180465 — intervention group
Group type: EXPERIMENTAL
Intervention: ToR lead time of 6-60 seconds
Number of subjects: 31
Study 35180465 — intervention group
Group type: EXPERIMENTAL
Intervention: ToR lead time of 16-30 seconds
Number of subjects: 31
Study 34817964 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass hybrid (GH; EQUIA Forte Fil/EQUIA Forte Coat, GC)
Number of subjects: 88
Study 34817964 — intervention group
Group type: COMPARATOR
Intervention: Adhesive/nanofilled resin composite restorations (RC; OptiBond FL, Kerr/Filtek Supreme XTE, 3M Oral Care)
Number of subjects: 88
Study 34013819 — intervention group
Group type: EXPERIMENTAL
Intervention: SLE with prior severe organ manifestation
Number of subjects: 34
Study 34013819 — intervention group
Group type: COMPARATOR
Intervention: SLE without prior severe organ manifestation
Number of subjects: 34
Study 32245584 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO-AGE scoring system
Number of subjects: 5025
Study 33844620 — intervention group
Group type: EXPERIMENTAL
Intervention: Multipass low fluence, high-frequency 755-nm Alexandrite laser
Number of subjects: 30
Study 33844620 — intervention group
Group type: COMPARATOR
Intervention: High fluence, low-frequency 1064-nm long-pulsed Nd: YAG laser
Number of subjects: 30
Study 32479556 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrumentality-based pro-diversity beliefs
Number of subjects: 0
Study 32479556 — intervention group
Group type: EXPERIMENTAL
Intervention: Actual instrumentality of ethnic diversity
Number of subjects: 0
Study 35505308 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive score for atypical pathogens (AP)
Number of subjects: 580
Study 35505308 — intervention group
Group type: EXPERIMENTAL
Intervention: Age < 75 years
Number of subjects: 580
Study 35505308 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure
Number of subjects: 580
Study 35505308 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of chest pain
Number of subjects: 580
Study 35505308 — intervention group
Group type: EXPERIMENTAL
Intervention: Natremia < 135 mmol/L
Number of subjects: 580
Study 35505308 — intervention group
Group type: EXPERIMENTAL
Intervention: Contracting the disease in autumn
Number of subjects: 580
Study 33132228 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran (150 or 110 mg twice daily)
Number of subjects: 594
Study 33132228 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (100 mg once daily)
Number of subjects: 594
Study 35389963 — intervention group
Group type: EXPERIMENTAL
Intervention: BREAKS (intermittent walking for 2 min every 20 min at 6.4 km·h‐1)
Number of subjects: 10
Study 35389963 — intervention group
Group type: COMPARATOR
Intervention: SIT (sitting continuously for 5.5 hours)
Number of subjects: 10
Study 32126988 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaire development process
Number of subjects: 103000
Study 33459115 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task gait training (DTGT)
Number of subjects: 36
Study 33459115 — intervention group
Group type: COMPARATOR
Intervention: Single-task gait training (STGT)
Number of subjects: 36
Study 33459115 — intervention group
Group type: EXPERIMENTAL
Intervention: Both DTGT and STGT
Number of subjects: 36
Study 34410769 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback condition (n = 147) with access to patient-generated outcome (ORS) and alliance information.
Number of subjects: 280
Study 34410769 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU; n = 133).
Number of subjects: 280
Study 32083994 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive RBC transfusion strategy (Hb threshold < 70 g/L)
Number of subjects: 300
Study 32083994 — intervention group
Group type: COMPARATOR
Intervention: Liberal RBC transfusion strategy (Hb threshold < 90 g/L)
Number of subjects: 300
Study 36049354 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning-based EEG analysis
Number of subjects: 358
Study 36049354 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning-based EEG analysis with certainty factor ≥ 60%
Number of subjects: 358
Study 36049354 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning-based EEG analysis with certainty factor ≥ 75%
Number of subjects: 358
Study 34032387 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended contact with community-dwelling older adults and positive theoretical education
Number of subjects: 55
Study 34032387 — intervention group
Group type: COMPARATOR
Intervention: Positive theoretical education only (Control group)
Number of subjects: 55
Study 34032387 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Intervention and Control)
Number of subjects: 55
Study 34393020 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rotavirus vaccine (RVV)
Number of subjects: 158
Study 34393020 — intervention group
Group type: EXPERIMENTAL
Intervention: Gut microbiome composition
Number of subjects: 158
Study 34393020 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacteroides thetaiotaomicron
Number of subjects: 158
Study 34393020 — intervention group
Group type: EXPERIMENTAL
Intervention: Random forest models
Number of subjects: 158
Study 32142484 — intervention group
Group type: EXPERIMENTAL
Intervention: C+COX‐2‐Is (convention plus COX‐2 inhibitors)
Number of subjects: 190
Study 32142484 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib
Number of subjects: 190
Study 35786298 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-session psychological intervention in primary care
Number of subjects: 220
Study 33650616 — intervention group
Group type: EXPERIMENTAL
Intervention: MC‐LASSO‐PLS
Number of subjects: 0
Study 33650616 — intervention group
Group type: COMPARATOR
Intervention: LASSO‐PLS
Number of subjects: 0
Study 33650616 — intervention group
Group type: COMPARATOR
Intervention: MC‐PLS
Number of subjects: 0
Study 33650616 — intervention group
Group type: COMPARATOR
Intervention: PLS
Number of subjects: 0